December 8, 2016 / 12:14 PM / 7 months ago

BRIEF-Edwards Lifesciences sees 2017 global sales of $3.0 bln to $3.4 bln

1 Min Read

Dec 8 (Reuters) - Edwards Lifesciences Corp :

* Sees 2017 global sales of $3.0 billion to $3.4 billion; sees 2017 adjusted earnings per share $3.30 to $3.45

* Q4 sales are trending towards lower end of guidance

* Sees 2017 Transcatheter Heart Valve Therapy sales of $1.7 billion to $2.0 billion

* Q4 Surgical Heart Valve Therapy sales trending below oct guidance; Q4 critical care sales are trending consistent with guidance

* Sees Q4 2016 Transcatheter Heart Valve Therapy sales in the range of $415 million to $430 million

* Sees 2017 surgical heart valve therapy sales of $750 million to $790 million

* In 2017, continues to anticipate european regulatory approval for Edwards Sapien 3 Ultra System, Edwards Centera Valve System

* Sees 2017 critical care sales of $560 million to $600 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below